Informed consent: time for more transparency

Informed consent is not only for documenting a patient's acceptance of enrolling in a clinical trial. It currently is the patient's and, we propose, should also be the public's main source of information regarding the reasons for the planned study, what is known in the field about the...

Descripción completa

Detalles Bibliográficos
Autores principales: Yazici, Yusuf, Yazici, Hasan
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2911861/
https://www.ncbi.nlm.nih.gov/pubmed/20537202
http://dx.doi.org/10.1186/ar3004
_version_ 1782184523949146112
author Yazici, Yusuf
Yazici, Hasan
author_facet Yazici, Yusuf
Yazici, Hasan
author_sort Yazici, Yusuf
collection PubMed
description Informed consent is not only for documenting a patient's acceptance of enrolling in a clinical trial. It currently is the patient's and, we propose, should also be the public's main source of information regarding the reasons for the planned study, what is known in the field about the proposed trial, and what to expect as far as efficacy and harm. Informed consent is not currently part of the clinical trial registries. For purposes of full disclosure to the patients and the public, the informed consent should be part of the required documents for such registries.
format Text
id pubmed-2911861
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29118612010-12-03 Informed consent: time for more transparency Yazici, Yusuf Yazici, Hasan Arthritis Res Ther Commentary Informed consent is not only for documenting a patient's acceptance of enrolling in a clinical trial. It currently is the patient's and, we propose, should also be the public's main source of information regarding the reasons for the planned study, what is known in the field about the proposed trial, and what to expect as far as efficacy and harm. Informed consent is not currently part of the clinical trial registries. For purposes of full disclosure to the patients and the public, the informed consent should be part of the required documents for such registries. BioMed Central 2010 2010-06-03 /pmc/articles/PMC2911861/ /pubmed/20537202 http://dx.doi.org/10.1186/ar3004 Text en Copyright ©2010 BioMed Central Ltd
spellingShingle Commentary
Yazici, Yusuf
Yazici, Hasan
Informed consent: time for more transparency
title Informed consent: time for more transparency
title_full Informed consent: time for more transparency
title_fullStr Informed consent: time for more transparency
title_full_unstemmed Informed consent: time for more transparency
title_short Informed consent: time for more transparency
title_sort informed consent: time for more transparency
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2911861/
https://www.ncbi.nlm.nih.gov/pubmed/20537202
http://dx.doi.org/10.1186/ar3004
work_keys_str_mv AT yaziciyusuf informedconsenttimeformoretransparency
AT yazicihasan informedconsenttimeformoretransparency

Ejemplares similares